1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Cerebral Ischemia in 42 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fasudil is believed to be at least equally effective as nimodipine for the prevention of cerebral vasospasm and subsequent ischemic injury in patients undergoing surgery for subarachnoid hemorrhage (SAH)." | 9.15 | Efficacy and safety of fasudil in patients with subarachnoid hemorrhage: final results of a randomized trial of fasudil versus nimodipine. ( Guo, J; Mao, Y; Ren, Z; Wang, R; Wang, S; Xu, B; Zhang, X; Zhang, Y; Zhao, J; Zhao, K; Zhou, D; Zhou, L, 2011) |
| " This randomized open trial with nimodipine as the control included 72 patients who underwent subarachnoid hemorrhage surgery for ruptured cerebral aneurysm of Hunt and Hess grades I to IV." | 9.12 | Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage. ( Guo, J; Ren, Z; Wang, R; Wang, S; Xu, B; Zhao, J; Zhou, D; Zhou, L, 2006) |
| "Treatment with fasudil within 48 h of acute ischemic stroke onset significantly improved the patient's clinical outcome." | 9.11 | Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. ( Hirai, S; Ohtomo, E; Satoh, S; Seto, M; Shibuya, M, 2005) |
| " To date, the only Rho-kinase inhibitor employed clinically in humans is fasudil, which has been used for the prevention of cerebral vasospasm and subsequent ischemic injury after surgery for subarachnoid hemorrhage (SAH)." | 8.90 | Pleiotropic effects of the rho-kinase inhibitor fasudil after subarachnoid hemorrhage: a review of preclinical and clinical studies. ( Asano, T; Ikegaki, I; Kawasaki, K; Satoh, S; Shibuya, M, 2014) |
| "Early CIMT promotes motor recovery after acute ischemic stroke when it is administered with fasudil pharmacotherapy, but not without it." | 7.83 | Combination of early constraint-induced movement therapy and fasudil enhances motor recovery after ischemic stroke in rats. ( Bonney, E; Chen, YH; Huang, FZ; Liu, BQ; Liu, YH; Wang, HX; Zhao, Y, 2016) |
| "Fasudil, a Rho-kinase inhibitor, is a promising neuroprotectant against ischemic stroke; however, its low bioavailability is an obstacle to be overcome." | 7.83 | Neuroprotection against cerebral ischemia/reperfusion injury by intravenous administration of liposomal fasudil. ( Asai, T; Fukuta, T; Kikuchi, T; Koide, H; Namba, M; Oku, N; Sato, A; Shimizu, K; Yanagida, Y, 2016) |
| "CaMKII interacted with nNOS and regulated serine phosphorylation of nNOS during brain ischemia." | 7.72 | Brain ischemia induces serine phosphorylation of neuronal nitric oxide synthase by Ca(2+)/calmodulin-dependent protein kinase II in rat hippocampus. ( Meng, FJ; Song, B; Yan, XB; Zhang, GY, 2004) |
| "The effects of an intracellular calcium antagonist fasudil (HA 1077) on protein synthesis, ion derangement, brain edema, and the neurological signs associated with focal cerebral ischemia, were investigated via a nine-hour occlusion of the left common carotid artery (CCA) in Mongolian gerbils." | 7.69 | Fasudil (HA1077), an intracellular calcium antagonist, improves neurological deficits and tissue potassium loss in focal cerebral ischemia in gerbils. ( Kondoh, Y; Mizusawa, S; Murakami, M; Nagata, K; Nakamichi, H, 1997) |
| "Brain ischemia was induced by the four-vessel occlusion method on Sprague-Dawley rats." | 5.32 | Cerebral ischemia immediately increases serine phosphorylation of the synaptic RAS-GTPase activating protein SynGAP by calcium/calmodulin-dependent protein kinase II alpha in hippocampus of rats. ( Guo, J; Meng, F; Song, B; Yan, X; Zhang, G, 2003) |
| "Fasudil is believed to be at least equally effective as nimodipine for the prevention of cerebral vasospasm and subsequent ischemic injury in patients undergoing surgery for subarachnoid hemorrhage (SAH)." | 5.15 | Efficacy and safety of fasudil in patients with subarachnoid hemorrhage: final results of a randomized trial of fasudil versus nimodipine. ( Guo, J; Mao, Y; Ren, Z; Wang, R; Wang, S; Xu, B; Zhang, X; Zhang, Y; Zhao, J; Zhao, K; Zhou, D; Zhou, L, 2011) |
| " This randomized open trial with nimodipine as the control included 72 patients who underwent subarachnoid hemorrhage surgery for ruptured cerebral aneurysm of Hunt and Hess grades I to IV." | 5.12 | Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage. ( Guo, J; Ren, Z; Wang, R; Wang, S; Xu, B; Zhao, J; Zhou, D; Zhou, L, 2006) |
| "Treatment with fasudil within 48 h of acute ischemic stroke onset significantly improved the patient's clinical outcome." | 5.11 | Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. ( Hirai, S; Ohtomo, E; Satoh, S; Seto, M; Shibuya, M, 2005) |
| " To date, the only Rho-kinase inhibitor employed clinically in humans is fasudil, which has been used for the prevention of cerebral vasospasm and subsequent ischemic injury after surgery for subarachnoid hemorrhage (SAH)." | 4.90 | Pleiotropic effects of the rho-kinase inhibitor fasudil after subarachnoid hemorrhage: a review of preclinical and clinical studies. ( Asano, T; Ikegaki, I; Kawasaki, K; Satoh, S; Shibuya, M, 2014) |
| "Early CIMT promotes motor recovery after acute ischemic stroke when it is administered with fasudil pharmacotherapy, but not without it." | 3.83 | Combination of early constraint-induced movement therapy and fasudil enhances motor recovery after ischemic stroke in rats. ( Bonney, E; Chen, YH; Huang, FZ; Liu, BQ; Liu, YH; Wang, HX; Zhao, Y, 2016) |
| "Fasudil, a Rho-kinase inhibitor, is a promising neuroprotectant against ischemic stroke; however, its low bioavailability is an obstacle to be overcome." | 3.83 | Neuroprotection against cerebral ischemia/reperfusion injury by intravenous administration of liposomal fasudil. ( Asai, T; Fukuta, T; Kikuchi, T; Koide, H; Namba, M; Oku, N; Sato, A; Shimizu, K; Yanagida, Y, 2016) |
| "We investigated the neuroprotective effects of fasudil's active metabolite, hydroxyfasudil, a Rho-kinase inhibitor, in a rat stroke model in which endothelial damage and subsequent thrombotic occlusion were selectively induced in perforating arteries." | 3.76 | Amelioration of endothelial damage/dysfunction is a possible mechanism for the neuroprotective effects of Rho-kinase inhibitors against ischemic brain damage. ( Asano, T; Hitomi, A; Ikegaki, I; Iwasaki, M; Kawasaki, K; Mohri, M; Nakazono, O; Satoh, S, 2010) |
| "Recently, fasudil, a Rho kinase (ROCK) inhibitor, was reported to prevent cerebral ischemia in vivo by increasing cerebral blood flow and inhibiting inflammatory responses." | 3.74 | Fasudil, a Rho kinase (ROCK) inhibitor, protects against ischemic neuronal damage in vitro and in vivo by acting directly on neurons. ( Hara, H; Iwama, T; Kotani, Y; Nakajima, Y; Nakashima, S; Shimazawa, M; Yamashita, K; Yoshimura, S, 2007) |
| " In this study, we assessed the temporal and spatial profiles of Rho-kianse activity and the effect of the Rho-kinase inhibitor fasudil on microcirculatory disturbances in the focal brain ischemia." | 3.74 | Rho-kinase activation in endothelial cells contributes to expansion of infarction after focal cerebral ischemia. ( Hori, M; Kaibuchi, K; Kitagawa, K; Omura-Matsuoka, E; Sasaki, T; Terasaki, Y; Todo, K; Yagita, Y, 2007) |
| "CaMKII interacted with nNOS and regulated serine phosphorylation of nNOS during brain ischemia." | 3.72 | Brain ischemia induces serine phosphorylation of neuronal nitric oxide synthase by Ca(2+)/calmodulin-dependent protein kinase II in rat hippocampus. ( Meng, FJ; Song, B; Yan, XB; Zhang, GY, 2004) |
| "The effects of an intracellular calcium antagonist fasudil (HA 1077) on protein synthesis, ion derangement, brain edema, and the neurological signs associated with focal cerebral ischemia, were investigated via a nine-hour occlusion of the left common carotid artery (CCA) in Mongolian gerbils." | 3.69 | Fasudil (HA1077), an intracellular calcium antagonist, improves neurological deficits and tissue potassium loss in focal cerebral ischemia in gerbils. ( Kondoh, Y; Mizusawa, S; Murakami, M; Nagata, K; Nakamichi, H, 1997) |
| " In this review, we are introducing our new less-invasive intrathecal drug delivery system that provides an alternative and safe method to deliver therapeutic agents." | 2.43 | Safe and efficient drug delivery system with liposomes for intrathecal application of an antivasospastic drug, fasudil. ( Ishida, T; Kiwada, H; Takanashi, Y, 2006) |
| "To date, the pharmacologic approach to cerebral vasospasm and ischemia has been hampered in part by an inability to attain sufficiently high concentrations of drugs in the cerebrospinal fluid (CSF)." | 2.42 | [Development of drug delivery system for intrathecal administration and its therapeutic effect on cerebral vasospasm and ischemia]. ( Ishida, T, 2004) |
| "Hyperlipidemia is a major cardiovascular risk factor associated with progressive cerebrovascular dysfunction and diminished collateral perfusion in stroke." | 1.40 | Rho-kinase inhibition improves ischemic perfusion deficit in hyperlipidemic mice. ( Ayata, C; Huang, PL; Shin, HK, 2014) |
| "Chronic cerebral vasospasm was produced using a two-hemorrhage canine model." | 1.38 | Antivasospastic effects of hydroxyfasudil, a Rho-kinase inhibitor, after subarachnoid hemorrhage. ( Asano, T; Hitomi, A; Ikegaki, I; Kawasaki, K; Satoh, S; Shibuya, M; Takayasu, M; Yano, K, 2012) |
| "Cerebral ischemia was induced in rats by injecting 150 mug of sodium laurate into the left internal carotid artery on day 1." | 1.35 | Wide therapeutic time window for Rho-kinase inhibition therapy in ischemic brain damage in a rat cerebral thrombosis model. ( Asano, T; Hitomi, A; Ikegaki, I; Satoh, S; Seto, M; Toshima, Y, 2008) |
| "Brain ischemia was induced by the four-vessel occlusion method on Sprague-Dawley rats." | 1.32 | Cerebral ischemia immediately increases serine phosphorylation of the synaptic RAS-GTPase activating protein SynGAP by calcium/calmodulin-dependent protein kinase II alpha in hippocampus of rats. ( Guo, J; Meng, F; Song, B; Yan, X; Zhang, G, 2003) |
| "Brain ischemia was induced by four-vessel occlusion procedure in rats." | 1.32 | Competitive binding of postsynaptic density 95 and Ca2+-calmodulin dependent protein kinase II to N-methyl-D-aspartate receptor subunit 2B in rat brain. ( Guo, J; Meng, FJ; Song, B; Yan, XB; Zhang, GY, 2004) |
| "Pharmacological treatment for cerebral ischemia cannot attain sufficiently high concentrations of the drugs in the cerebrospinal fluid (CSF) without precipitating systemic side effects." | 1.31 | Neuroprotection by intrathecal application of liposome-entrapped fasudil in a rat model of ischemia. ( Allen, TM; Ishida, T; Kirchmeier, MJ; Shuaib, A; Takanashi, Y, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (23.81) | 18.2507 |
| 2000's | 18 (42.86) | 29.6817 |
| 2010's | 14 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukuta, T | 2 |
| Yanagida, Y | 2 |
| Asai, T | 2 |
| Oku, N | 2 |
| Shin, HK | 2 |
| Huang, PL | 2 |
| Ayata, C | 2 |
| Gibson, CL | 1 |
| Srivastava, K | 1 |
| Sprigg, N | 1 |
| Bath, PM | 1 |
| Bayraktutan, U | 1 |
| Satoh, S | 9 |
| Ikegaki, I | 8 |
| Kawasaki, K | 4 |
| Asano, T | 10 |
| Shibuya, M | 6 |
| Huang, L | 2 |
| Zhao, LB | 1 |
| Yu, ZY | 1 |
| He, XJ | 1 |
| Ma, LP | 1 |
| Li, N | 1 |
| Guo, LJ | 1 |
| Feng, WY | 1 |
| Liu, YH | 1 |
| Zhao, Y | 1 |
| Huang, FZ | 1 |
| Chen, YH | 1 |
| Wang, HX | 1 |
| Bonney, E | 1 |
| Liu, BQ | 1 |
| Wang, J | 1 |
| Wen, CY | 1 |
| Cui, CC | 1 |
| Xing, Y | 1 |
| Wang, M | 1 |
| Qi, DS | 1 |
| Zhou, C | 1 |
| Han, D | 1 |
| Li, PP | 1 |
| Zhang, F | 1 |
| Zhou, XY | 1 |
| Han, M | 1 |
| Di, JH | 1 |
| Ye, JS | 1 |
| Yu, HM | 1 |
| Song, YJ | 1 |
| Zhang, GY | 4 |
| Sato, A | 1 |
| Namba, M | 1 |
| Kikuchi, T | 1 |
| Koide, H | 1 |
| Shimizu, K | 1 |
| Feske, SK | 1 |
| Sorond, FA | 1 |
| Henderson, GV | 1 |
| Seto, M | 4 |
| Hitomi, A | 5 |
| Sasaki, Y | 2 |
| Liao, JK | 3 |
| Nakazono, O | 1 |
| Iwasaki, M | 1 |
| Mohri, M | 1 |
| Zhao, J | 2 |
| Zhou, D | 2 |
| Guo, J | 4 |
| Ren, Z | 2 |
| Zhou, L | 2 |
| Wang, S | 2 |
| Zhang, Y | 1 |
| Xu, B | 3 |
| Zhao, K | 1 |
| Wang, R | 2 |
| Mao, Y | 1 |
| Zhang, X | 1 |
| Takayasu, M | 1 |
| Yano, K | 2 |
| Jonassen, AK | 1 |
| Wergeland, A | 1 |
| Helgeland, E | 1 |
| Mjøs, OD | 1 |
| Brar, BK | 1 |
| Wu, J | 1 |
| Li, J | 1 |
| Hu, H | 1 |
| Liu, P | 1 |
| Fang, Y | 1 |
| Wu, D | 1 |
| Song, B | 3 |
| Meng, F | 1 |
| Yan, X | 1 |
| Zhang, G | 1 |
| Meng, FJ | 2 |
| Yan, XB | 2 |
| Ishida, T | 3 |
| Hirai, S | 1 |
| Ohtomo, E | 1 |
| Hao, ZB | 1 |
| Pei, DS | 1 |
| Guan, QH | 1 |
| Rikitake, Y | 1 |
| Kim, HH | 1 |
| Huang, Z | 1 |
| Moskowitz, MA | 2 |
| Takanashi, Y | 2 |
| Kiwada, H | 1 |
| Salomone, S | 1 |
| Potts, EM | 1 |
| Lee, SW | 1 |
| Millican, E | 1 |
| Noma, K | 1 |
| Boas, DA | 1 |
| Yamashita, K | 1 |
| Kotani, Y | 1 |
| Nakajima, Y | 1 |
| Shimazawa, M | 1 |
| Yoshimura, S | 1 |
| Nakashima, S | 1 |
| Iwama, T | 1 |
| Hara, H | 1 |
| Yagita, Y | 1 |
| Kitagawa, K | 1 |
| Sasaki, T | 1 |
| Terasaki, Y | 1 |
| Todo, K | 1 |
| Omura-Matsuoka, E | 1 |
| Kaibuchi, K | 1 |
| Hori, M | 1 |
| He, Z | 1 |
| Guo, L | 1 |
| Wang, H | 1 |
| Toshima, Y | 1 |
| Zabøocka, B | 1 |
| Domańska-Janik, K | 1 |
| Louis, JC | 1 |
| Magal, E | 1 |
| Gerdes, W | 1 |
| Seifert, W | 1 |
| Maiese, K | 1 |
| Wagner, J | 1 |
| Boccone, L | 1 |
| Kawamura, S | 1 |
| Yasui, N | 1 |
| Shirasawa, M | 1 |
| Fukasawa, H | 1 |
| Suzuki, Y | 3 |
| Hidaka, H | 2 |
| Kondoh, Y | 1 |
| Mizusawa, S | 1 |
| Murakami, M | 1 |
| Nakamichi, H | 1 |
| Nagata, K | 1 |
| Nakane, H | 1 |
| Yao, H | 1 |
| Ibayashi, S | 1 |
| Kitazono, T | 1 |
| Ooboshi, H | 1 |
| Uchimura, H | 1 |
| Fujishima, M | 1 |
| Hu, ZL | 1 |
| Tan, YX | 1 |
| Zhang, JP | 1 |
| Qian, DH | 1 |
| Kobayashi, T | 2 |
| Yoshida, J | 1 |
| Kirchmeier, MJ | 1 |
| Shuaib, A | 1 |
| Allen, TM | 1 |
| Utsunomiya, T | 1 |
| Tsurui, K | 1 |
| Tanaka, Y | 1 |
| Masuzawa, T | 1 |
| Saito, M | 1 |
| Yamada, T | 1 |
| Ebihara, A | 1 |
| Iwasa, H | 1 |
| Mori, S | 1 |
| Mochizuki, D | 1 |
| Sugita, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Neuroprotective Effect of Dapsone in Patients With Aneurysmal Subarachnoid Hemorrhage: Prospective, Randomized, Double-Blinded, Placebo-Controlled, Clinical Trial[NCT05131295] | Phase 3 | 49 participants (Actual) | Interventional | 2007-09-05 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Cerebral Ischemia
| Article | Year |
|---|---|
Pleiotropic effects of the rho-kinase inhibitor fasudil after subarachnoid hemorrhage: a review of preclinical and clinical studies.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Ischemia; Clinical Trials as Topic; Dr | 2014 |
[Development of drug delivery system for intrathecal administration and its therapeutic effect on cerebral vasospasm and ischemia].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Ischemia; Delayed-Action Preparations; | 2004 |
Safe and efficient drug delivery system with liposomes for intrathecal application of an antivasospastic drug, fasudil.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Ischemia; Chemistry, Pharmaceutical; C | 2006 |
3 trials available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Cerebral Ischemia
| Article | Year |
|---|---|
Efficacy and safety of fasudil in patients with subarachnoid hemorrhage: final results of a randomized trial of fasudil versus nimodipine.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Brain Ischemia; Calcium Channel Blockers | 2011 |
Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acute Disease; Aged; Brain Ischemia; Dose-Response Re | 2005 |
Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Brain Ischemia; Female; Humans; Male; Middle A | 2006 |
36 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Cerebral Ischemia
| Article | Year |
|---|---|
Co-administration of liposomal fasudil and tissue plasminogen activator ameliorated ischemic brain damage in occlusion model rats prepared by photochemically induced thrombosis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Ischemia; Drug Combinations; Fibrinoly | 2018 |
Rho-kinase inhibition improves ischemic perfusion deficit in hyperlipidemic mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Ischemia; Cerebrovascular Circulation; | 2014 |
Inhibition of Rho-kinase protects cerebral barrier from ischaemia-evoked injury through modulations of endothelial cell oxidative stress and tight junctions.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Astrocytes; Blood-Brain Barrier; Blo | 2014 |
Long-term inhibition of Rho-kinase restores the LTP impaired in chronic forebrain ischemia rats by regulating GABAA and GABAB receptors.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Ischemia; Chronic Disease; Disease Mod | 2014 |
Combination of early constraint-induced movement therapy and fasudil enhances motor recovery after ischemic stroke in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Analysis of Variance; Animals; Brain Infarction; Brai | 2016 |
Effect of activation of the Ca(2+)-permeable acid-sensing ion channel 1a on focal cerebral ischemia in diabetic rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acid Sensing Ion Channels; Animals; Brain; Brain Isch | 2015 |
Ischemic preconditioning protects the brain against injury via inhibiting CaMKII-nNOS signaling pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Apoptosis; Brain Ischemia; CA1 Region, Hippo | 2016 |
Neuroprotection against cerebral ischemia/reperfusion injury by intravenous administration of liposomal fasudil.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Intravenous; Animals; Brain; Brain Is | 2016 |
Increased leukocyte ROCK activity in patients after acute ischemic stroke.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Blotting, Western; Brain Ischemia; Enzyme Inhib | 2009 |
Amelioration of endothelial damage/dysfunction is a possible mechanism for the neuroprotective effects of Rho-kinase inhibitors against ischemic brain damage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain; Brain Ischemia; Capillary Permeabilit | 2010 |
Antivasospastic effects of hydroxyfasudil, a Rho-kinase inhibitor, after subarachnoid hemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Viscosity; Brain Ischemia; Disease Mod | 2012 |
Activation of corticotropin releasing factor receptor type 2 in the heart by corticotropin releasing factor offers cytoprotection against ischemic injury via PKA and PKC dependent signaling.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Ischemia; Cell Death; Corticotropin-Re | 2012 |
Rho-kinase inhibitor, fasudil, prevents neuronal apoptosis via the Akt activation and PTEN inactivation in the ischemic penumbra of rat brain.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Apoptosis; Brain; Brain Ischemia; Male; Neur | 2012 |
Cerebral ischemia immediately increases serine phosphorylation of the synaptic RAS-GTPase activating protein SynGAP by calcium/calmodulin-dependent protein kinase II alpha in hippocampus of rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Ischemia; Calcium-Calmodulin-Dependent | 2003 |
Competitive binding of postsynaptic density 95 and Ca2+-calmodulin dependent protein kinase II to N-methyl-D-aspartate receptor subunit 2B in rat brain.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Binding, Competitive; Brain Ischemia; Calciu | 2004 |
Brain ischemia induces serine phosphorylation of neuronal nitric oxide synthase by Ca(2+)/calmodulin-dependent protein kinase II in rat hippocampus.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Ischemia; Calcium-Calmodulin-Dependent | 2004 |
Calcium/calmodulin-dependent protein kinase II (CaMKII), through NMDA receptors and L-Voltage-gated channels, modulates the serine phosphorylation of GluR6 during cerebral ischemia and early reperfusion period in rat hippocampus.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Analysis of Variance; Animals; Brain Ischemia; Calciu | 2005 |
Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Analysis of Variance; Animals; Antihypertensi | 2005 |
Rho-kinase inhibition acutely augments blood flow in focal cerebral ischemia via endothelial mechanisms.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetylcholine; Animals; Brain Ischemia; Cerebrovascul | 2007 |
Fasudil, a Rho kinase (ROCK) inhibitor, protects against ischemic neuronal damage in vitro and in vivo by acting directly on neurons.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Ischemia; Cell Survival; Dose-Response | 2007 |
Rho-kinase activation in endothelial cells contributes to expansion of infarction after focal cerebral ischemia.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain; Brain Infarction; Brain Ischemia; Cal | 2007 |
Improvement of cognitive deficit and neuronal damage in rats with chronic cerebral ischemia via relative long-term inhibition of rho-kinase.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Infarction; Brain Ischemia; Cerebral C | 2008 |
Wide therapeutic time window for Rho-kinase inhibition therapy in ischemic brain damage in a rat cerebral thrombosis model.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antipyrine; Blood Flow Velocity; Brain Ische | 2008 |
PAF antagonist, BN52021, inhibits [3H]D-aspartate release after ischaemia in vitro.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Aspartic Acid; Brain Ischemia; Diterpenes; E | 1994 |
Survival-promoting and protein kinase C-regulating roles of basic FGF for hippocampal neurons exposed to phorbol ester, glutamate and ischaemia-like conditions.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amino Acid Sequence; Animals; Brain Ischemia; Cell Su | 1993 |
Nitric oxide: a downstream mediator of calcium toxicity in the ischemic cascade.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Ischemia; Calcium; Cell Death; Cells, | 1994 |
AT-877, a Ca2+ antagonist, fails to reduce infarct size following rat middle-cerebral artery occlusion.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Glucose; Blood Pressure; Brain Ischemi | 1993 |
Neuroprotective properties of a protein kinase inhibitor against ischaemia-induced neuronal damage in rats and gerbils.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Body Water; Brain Chemistry; Brain Ischemia; | 1996 |
Fasudil (HA1077), an intracellular calcium antagonist, improves neurological deficits and tissue potassium loss in focal cerebral ischemia in gerbils.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Body Water; Brain; Brain Edema; Brain Ischem | 1997 |
Protein kinase C modulates ischemia-induced amino acids release in the striatum of hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amino Acids; Animals; Brain Ischemia; Corpus Striatum | 1998 |
[Effects of inhibitor of protein kinase C on brain edema formation evoked by experimental cerebral ischemia in gerbils and rats].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Alkaloids; Animals; Brain Edema; Brain Ischemia; Gerb | 1996 |
Inhibition of neutrophil migration by a protein kinase inhibitor for the treatment of ischemic brain infarction.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Ischemia; Chemotaxis, Leukocyte; Enzym | 1999 |
Neuroprotection by intrathecal application of liposome-entrapped fasudil in a rat model of ischemia.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Damage, Chronic; Brain Ischemia; Cereb | 2001 |
Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain; Brain Ischemia; Cerebral Arteries; Do | 2001 |
Combined administration of Fasudil hydrochloride and nitroglycerin for treatment of cerebral vasospasm.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Brain Ischemia; Drug Combinations; Female; Huma | 2001 |
Blockade of intracellular actions of calcium may protect against ischaemic damage to the gerbil brain.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Ischemia; Calcimycin; Calcium Channel | 1991 |